Search results
Results from the WOW.Com Content Network
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
Following the Mediterranean diet may lower the risk for Covid-19 infection, but whether the diet reduces case severity is unclear, according to new research.
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, [1] is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, [24] and its Belgian parent company Janssen Pharmaceuticals, [25] a subsidiary of American company Johnson & Johnson.
Everyone ages six months and older should get the 2024–2025 COVID-19 vaccine, advises Richard Watkins, M.D., an infectious disease physician and professor of medicine at the Northeast Ohio ...
The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease. [24]